Arcutis Biotherapeutics, Inc.

How big is Arcutis Biotherapeutics, Inc.?

As of Jun 18, Arcutis Biotherapeutics, Inc. has a market capitalization of 1,582.36 million, with recent net sales of 212.83 million and a net profit of -129.72 million. The company reported shareholder's funds of 157.54 million and total assets of 348.89 million as of Dec 24.

Market Cap: As of Jun 18, Arcutis Biotherapeutics, Inc. has a market capitalization of 1,582.36 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Arcutis Biotherapeutics, Inc. reported net sales of 212.83 million and a net profit of -129.72 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 157.54 million and total assets of 348.89 million.

What does Arcutis Biotherapeutics, Inc. do?

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing treatments for dermatological diseases. As of March 2025, it reported net sales of $66 million and a net loss of $25 million, with a market cap of approximately $1.58 billion.

Overview:<BR>Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 66 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -25 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,582.36 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.63 <BR>Return on Equity: -91.38% <BR>Price to Book: 11.09<BR><BR>Contact Details:<BR>Address: 2945 Townsgate Road, Suite 110, WESTLAKE VILLAGE CA: 91361 <BR>Tel: 1 805 4185006 <BR>Fax: 1 302 5313150 <BR>Website: https://arcutis.com/

Should I buy, sell or hold Arcutis Biotherapeutics, Inc.?

Who are in the management team of Arcutis Biotherapeutics, Inc.?

As of March 2022, the management team of Arcutis Biotherapeutics, Inc. includes Patrick Heron (Independent Chairman), Todd Watanabe (CEO), and directors Terrie Curran, Halley Gilbert, Howard Welgus, Bhaskar Chaudhuri, and Jonathan Silverstein. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Arcutis Biotherapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Patrick Heron, Independent Chairman of the Board<BR>- Mr. Todd Watanabe, President, Chief Executive Officer, and Director<BR>- Ms. Terrie Curran, Director<BR>- Ms. Halley Gilbert, Director<BR>- Dr. Howard Welgus, Director<BR>- Dr. Bhaskar Chaudhuri, Independent Director<BR>- Mr. Jonathan Silverstein, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Arcutis Biotherapeutics, Inc. overvalued or undervalued?

As of February 28, 2023, Arcutis Biotherapeutics, Inc. is considered a risky investment due to its overvaluation, highlighted by a Price to Book Value of 12.02 and a negative ROCE of -231.44%, despite a year-to-date return of 27.14% that outperformed the S&P 500, which has a long-term return contrast of -32.76% versus the index's 96.61%.

As of 28 February 2023, the valuation grade for Arcutis Biotherapeutics, Inc. has moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 12.02, an EV to Sales ratio of 7.63, and a ROCE of -231.44%. Compared to peers, Arcutis has a significantly higher EV to EBITDA ratio of -14.01, while ARS Pharmaceuticals, Inc. has an EV to EBITDA of -13.96, and Arbutus Biopharma Corp. shows -17.47, indicating that Arcutis is less favorable in terms of valuation.<BR><BR>In terms of recent performance, Arcutis has outperformed the S&P 500 with a year-to-date return of 27.14% compared to the index's 12.22%. However, the long-term outlook remains concerning, as evidenced by a 5-year return of -32.76%, which starkly contrasts with the S&P 500's 96.61% return over the same period.

Is Arcutis Biotherapeutics, Inc. technically bullish or bearish?

As of August 12, 2025, Arcutis Biotherapeutics, Inc. shows a bullish trend supported by strong technical indicators, outperforming the S&P 500 in the short term but underperforming over the past 3 and 5 years.

As of 12 August 2025, the technical trend for Arcutis Biotherapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view: the MACD is bullish on both weekly and monthly time frames, Bollinger Bands are bullish, and the On-Balance Volume (OBV) is also bullish. The daily moving averages confirm this bullish trend. However, the Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. <BR><BR>In terms of performance, Arcutis has outperformed the S&P 500 over the past week (0.11% vs. 1.05%), month (5.79% vs. 2.33%), year-to-date (27.14% vs. 12.22%), and year (70.29% vs. 17.14%). However, it has underperformed over the longer 3-year and 5-year periods.